Juliana Hamzah

Dr. Juliana Hamzah


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Clinical Therapeutics
Verified
Journal Article
Closed access
HKHaritha Kirla
Haritha Kirla
DHDavid J. Henry
David J. Henry
SJShirley Jansen
Shirley Jansen
PTPeter L. Thompson
Peter L. Thompson
JHJuliana Hamzah
Juliana Hamzah

11 November 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
YYYen Ling Yeow
Yen Ling Yeow
VKVenkata Ramana Kotamraju
Venkata Ramana Kotamraju
XWXiao Wang
Xiao Wang
MCMeenu Chopra
Meenu Chopra
NANasibah Azme
Nasibah Azme
JHJuliana Hamzah
Juliana Hamzah
High extracellular matrix (ECM) content in solid cancers impairs tumour perfusion and thus access of imaging and therapeutic agents. We have devised a new approach to degrade tumour ECM, which improves uptake of circulating compounds. We target the immune‐modulating cytokine, tumour necrosis factor alpha (TNFα), to tumours using a newly discovered peptide ligand referred to as CSG. This peptide binds to laminin–nidogen complexes in the ECM of mouse and human carcinomas with little or no peptide detected in normal tissues, and it selectively delivers a recombinant TNFα‐CSG fusion protein to tumour ECM in tumour‐bearing mice. Intravenously injected TNFα‐CSG triggered robust immune cell infiltration in mouse tumours, particularly in the ECM‐rich zones. The immune cell influx was accompanied by extensive ECM degradation, reduction in tumour stiffness, dilation of tumour blood vessels, improved perfusion and greater intratumoral uptake of the contrast agents gadoteridol and iron oxide nanoparticles. Suppressed tumour growth and prolonged survival of tumour‐bearing mice were observed. These effects were attainable without the usually severe toxic side effects of TNFα.

1 September 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZSZhi-Gang She
Zhi-Gang She
JHJuliana Hamzah
Juliana Hamzah
VKVenkata R. Kotamraju
Venkata R. Kotamraju
HPHong-Bo Pang
Hong-Bo Pang
SJShirley Jansen
Shirley Jansen
ERErkki Ruoslahti
Erkki Ruoslahti

30 March 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
HBHanane Belhoul-Fakir
Hanane Belhoul-Fakir
JWJiansha Wu
Jiansha Wu
YYYen L. Yeow
Yen L. Yeow
GMGabrielle C. Musk
Gabrielle C. Musk
HKHelen Kershaw
Helen Kershaw
SJShirley Jansen
Shirley Jansen
Background and aims: Fatty streaks initiating the formation of atheromatous plaque appear in the tunica intima. The tunica media is not known to be a nidus for lipid accumulation initiating atherogenesis. We assessed changes to the tunica media in response to a micro-injury produced in the pig aorta. In addition, we assessed human carotid endarterectomy plaques for indication of atheroma initiation in the tunica media.Methods: Three healthy landrace female pigs underwent laparotomy to inject autologous blood and create micro-hematomas at 6 sites within the tunica media of the infrarenal abdominal aorta. These pigs were fed a high-fat diet (HFD) for 4–12 weeks. Post-mortem aortas from all pigs, including a control group of healthy pigs, were serially stained to detect lipid deposits, vasa vasora (VV), immune cell infiltration and inflammatory markers, as well as changes to the vascular smooth muscle cell (vSMC) compartment. Moreover, 25 human carotid endarterectomy (CEA) specimens were evaluated for their lipid composition in the tunica media and intima.Results: High lipid clusters, VV density, and immune cell infiltrates were consistently observed at 5 out of 6 injection sites under prolonged hyperlipidemia. The hyperlipidemic diet also affected the vSMC compartment in the tunica media adjacent to the tunica adventitia, which correlated with VV invasion and immune cell infiltration. Analysis of human carotid specimens post-CEA indicated that 32% of patients had significantly greater atheroma in the tunica media than in the arterial intima.Conclusion: The arterial intima is not the only site for atherosclerosis initiation. We show that injury to the media can trigger atherogenesis.

12 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MCMeenu Chopra
Meenu Chopra
JWJiansha Wu
Jiansha Wu
YYYen Yeow
Yen Yeow
LWLouise Winteringham
Louise Winteringham
TCTristan D. Clemons
Tristan D. Clemons
JHJuliana Hamzah
Juliana Hamzah
Diagnostic imaging of aggressive cancer with a high stroma content may benefit from the use of imaging contrast agents targeted with peptides that have high binding affinity to the extracellular matrix (ECM). In this study, we report the use of superparamagnetic iron-oxide nanoparticles (IO-NP) conjugated to a nonapeptide, CSGRRSSKC (CSG), which specifically binds to the laminin-nidogen-1 complex in tumours. We show that CSG-IO-NP accumulate in tumours, predominantly in the tumour ECM, following intravenous injection into a murine model of pancreatic neuroendocrine tumour (PNET). In contrast, a control untargeted IO-NP consistently show poor tumour uptake, and IO-NP conjugated to a pentapeptide. CREKA that bind fibrin clots in blood vessels show restricted uptake in the angiogenic vessels of the tumours. CSG-IO-NP show three-fold higher intratumoral accumulation compared to CREKA-IO-NP. Magnetic resonance imaging (MRI) T2-weighted scans and T2 relaxation times indicate significant uptake of CSG-IO-NP irrespective of tumour size, whereas the uptake of CREKA-IO-NP is only consistent in small tumours of less than 3 mm in diameter. Larger tumours with significantly reduced tumour blood vessels show a lack of CREKA-IO-NP uptake. Our data suggest CSG-IO-NP are particularly useful for detecting stroma in early and advanced solid tumours.

27 November 2006 in International Journal for Parasitology
Verified
Journal Article
Closed access
JHJuliana Hamzah
Juliana Hamzah
Kevin T. BattyKevin T. Batty
Kevin T. Batty
WDWendy Davis
Wendy Davis
Trevor MoriTrevor Mori
Trevor Mori
SCS.Y.L. Ching
S.Y.L. Ching
Timothy M. E. DavisTimothy M. E. Davis
Timothy M. E. Davis